A phenotypic model recapitulating the neuropathology of Parkinson's disease

Brain and Behavior

Volumn 3, Issue 4, 2013, Pages 351-366

  Ferris, Craig F ^a   Marella, Mathieu ^b   Smerkers, Brian ^c   Barchet, Thomas M ^a   Gershman, Benjamin ^d   Matsuno Yagi, Akemi ^b   Yagi, Takao ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d InviCRO LLC   (United States)

Author keywords

DNA oxidation; Dopamine transporter; Lewy bodies; Oxidative stress; Rotenone; Tyrosine hydroxylase; Vesicular monoamine transporter

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CELL NUCLEUS DNA; DOPAMINE TRANSPORTER; IRON; ROTENONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; EXPERIMENTAL MODEL; FEMALE; HISTOPATHOLOGY; HYPOKINESIA; IMMUNOHISTOCHEMISTRY; IRON STORAGE; LEWY BODY; LONG EVANS RAT; MICROGLIA; MOTOR ACTIVITY; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; RAT; WEIGHT GAIN;

EID: 84893496168     PISSN: None     EISSN: 21623279     Source Type: Journal    
DOI: 10.1002/brb3.138     Document Type: Article

References (104)

1. Alam, Z. I., A. Jenner, S. E. Daniel, A. J. Lees, N. Cairns, C. D. Marsden, et al. 1997. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69:1196-1203.
2. Ballard, P. A., J. W. Tetrud, and J. W. Langston. 1985. Permanent human parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949-956.
3. Batchelor, P. E., G. T. Liberatore, J. Y. Wong, M. J. Porritt, F. Frerichs, G. A. Donnan, et al. 1999. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19:1708-1716.
4. Bellucci, A., L. Navarria, E. Falarti, M. Zaltieri, F. Bono, G. Collo, et al. 2011. Redistribution of DAT/alpha-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease. PLoS ONE 6:e27959.
5. Bernheimer, H., W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger. 1973. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:415-455.
6. Betarbet, R., T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:1301-1306.
7. Betarbet, R., R. M. Canet-Aviles, T. B. Sherer, P. G. Mastroberardino, C. McLendon, J. H. Kim, et al. 2006. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 22:404-420.
8. Bezard, E., S. Dovero, C. Imbert, T. Boraud, and C. E. Gross. 2000. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38:363-368.
9. Bharath, S., M. Hsu, D. Kaur, S. Rajagopalan, and J. K. Andersen. 2002. Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64:1037-1048.
10. Bindoff, L. A., M. Birch-Machin, N. E. Cartlidge, W. D. Parker Jr., and D. M. Turnbull. 1989. Mitochondrial function in Parkinson's disease. Lancet 2:49.
11. Blanchard, V., P. Anglade, G. Dziewczapolski, M. Savasta, Y. Agid, and R. Raisman-Vozari. 1996. Dopaminergic sprouting in the rat striatum after partial lesion of the substantia nigra. Brain Res. 709:319-325.
12. Blin, O., C. Desnuelle, O. Rascol, M. Borg, H. Peyro Saint Paul, J. P. Azulay, et al. 1994. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 125:95-101.
13. Block, M. L., and J. S. Hong. 2005. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76:77-98.
14. Bower, J. H., D. M. Maraganore, S. K. McDonnell, and W. A. Rocca. 2000. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov. Disord. 15:819-825.
15. Braak, H., and K. Del Tredici. 2008. Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered. Exp. Neurol. 212:226-229.
16. Braak, H., E. Braak, D. Yilmazer, C. Schultz, R. A. de Vos, and E. N. Jansen. 1995. Nigral and extranigral pathology in Parkinson's disease. J. Neural Transm. Suppl. 46:15-31.
17. Braak, H., E. Ghebremedhin, U. Rub, H. Bratzke, and K. Del Tredici. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318:121-134.
18. Brooks, D. J. 2010. Imaging dopamine transporters in Parkinson's disease. Biomark. Med. 4:651-660.
19. Cardellach, F., M. J. Martí, J. Fernández-Solá, C. Marín, J. B. Hoek, E. Tolosa, et al. 1993. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43:2258-2262.
20. Champy, P., G. U. Höglinger, J. Féger, C. Gleye, R. Hocquemiller, A. Laurens, et al. 2004. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88:63-69.
21. Delgado, M. 2003. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem. 278:27620-27629.
22. Dickson, D. W., H. Fujishiro, A. DelleDonne, J. Menke, Z. Ahmed, K. J. Klos, et al. 2008. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 115:437-444.
23. Dluzen, D. 1997. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 767:340-344.
24. Dravid, A., A. L. Jaton, A. Enz, and P. Frei. 1984. Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the substantia nigra. Brain Res. 311:361-365.
25. Eriksen, J., T. N. Jorgensen, and U. Gether. 2010. Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J. Neurochem. 113:27-41.
26. Fleming, L., J. B. Mann, J. Bean, T. Briggle, and J. R. Sanchez-Ramos. 1994. Parkinson's disease and brain levels of organochlorine pesticides. Ann. Neurol. 36:100-103.
27. Fleming, S. M., C. Zhu, P. O. Fernagut, A. Mehta, C. D. DiCarlo, R. L. Seaman, et al. 2004. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp. Neurol. 187:418-429.
28. Frey, K. A., R. A. Koeppe, M. R. Kilbourn, T. M. Vander Borght, R. L. Albin, S. Gilman, et al. 1996. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40:873-884.
29. Gao, X., and D. E. Dluzen. 2001. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 103:385-394.
30. Gao, H. M., J. S. Hong, W. Zhang, and B. Liu. 2002. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22:782-790.
31. Gao, H. M., B. Liu, and J. S. Hong. 2003a. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 23:6181-6187.
32. Gao, H. M., B. Liu, W. Zhang, and J. S. Hong. 2003b. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24:395-401.
33. Garcia-Reitböck, P., O. Anichtchik, A. Bellucci, M. Iovino, C. Ballini, E. Fineberg, et al. 2010. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133:2032-2044.
34. Götz, M. E., A. Dirr, W. Gsell, R. Burger, B. Janetzky, A. Freyberger, et al. 1994. Influence of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine, lipoic acid and L-deprenyl on the interplay between cellular redox systems. J. Neural Transm. Suppl. 43:145-162.
35. Greenamyre, J. T., G. MacKenzie, T. I. Peng, and S. E. Stephans. 1999. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66:85-97.
36. Guttman, M., J. Burkholder, S. J. Kish, D. Hussey, A. Wilson, J. DaSilva, et al. 1997. [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 48:1578-1583.
37. Gwinn-Hardy, K. 2002. Genetics of parkinsonism. Mov. Disord. 17:645-656.
38. Hirsch, E. C., J. P. Brandel, P. Galle, F. Javoy-Agid, and Y. Agid. 1991. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56:446-451.
39. Hsuan, S. L., H. M. Klintworth, and Z. Xia. 2006. Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways. J. Neurosci. 26:4481-4491.
40. Huang, J., H. Liu, W. Gu, Z. Yan, Z. Xu, Y. Yang, et al. 2006. A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease. Biomaterials 27:937-946.
41. Hunot, S., F. Boissière, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid, et al. 1996. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72:355-363.
42. Jenner, P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13(Suppl. 1):24-34.
43. Jennings, D. L., J. P. Seibyl, D. Oakes, S. Eberly, J. Murphy, and K. Marek. 2004. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch. Neurol. 61:1224-1229.
44. Kikuchi, A., A. Takeda, H. Onodera, T. Kimpara, K. Hisanaga, N. Sato, et al. 2002. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9:244-248.
45. Kilbourn, M. R., J. N. DaSilva, K. A. Frey, R. A. Koeppe, and D. E. Kuhl. 1993. In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography. J. Neurochem. 60:2315-2318.
46. Kim, W. G., R. P. Mohney, B. Wilson, G. H. Jeohn, B. Liu, and J. S. Hong. 2000. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20:6309-6316.
47. Knott, C., G. Stern, and G. P. Wilkin. 2000. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16:724-739.
48. Koutsilieri, E., C. Scheller, F. Tribl, and P. Riederer. 2002. Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism Relat. Disord. 8:401-406.
49. Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980.
50. Langston, J. W., L. S. Forno, J. Tetrud, A. G. Reeves, J. A. Kaplan, and D. Karluk. 1999. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann. Neurol. 46:598-605.
51. Lapointe, N., M. St-Hilaire, M. G. Martinoli, J. Blanchet, P. Gould, C. Rouillard, et al. 2004. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J. 18:717-719.
52. de Lau, L. M., and M. M. Breteler. 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5:525-535.
53. Lee, C. S., A. Samii, V. Sossi, T. J. Ruth, M. Schulzer, J. E. Holden, et al. 2000. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47:493-503.
54. Leranth, C., R. H. Roth, J. D. Elsworth, F. Naftolin, T. L. Horvath, and D. E. Redmond Jr. 2000. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J. Neurosci. 20:8604-8609.
55. Litvan, I., G. Halliday, M. Hallett, C. G. Goetz, W. Rocca, C. Duyckaerts, et al. 2007. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J. Neuropathol. Exp. Neurol. 66:251-257.
56. Liu, B., and J. S. Hong. 2003. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304:1-7.
57. Marek, K., R. Innis, C. van Dyck, B. Fussell, M. Early, S. Eberly, et al. 2001. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57:2089-2094.
58. Marella, M., B. B. Seo, A. Matsuno-Yagi, and T. Yagi. 2007. Mechanism of cell death caused by complex I defects in a rat dopaminergic cell line. J. Biol. Chem. 282:24146-24156.
59. Marella, M., B. B. Seo, E. Nakamaru-Ogiso, J. T. Greenamyre, A. Matsuno-Yagi, and T. Yagi. 2008. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 3:e1433.
60. Marshall, V. L., C. B. Reininger, M. Marquardt, J. Patterson, D. M. Hadley, W. H. Oertel, et al. 2009. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov. Disord. 24:500-508.
61. Martin, W. R., M. Wieler, A. J. Stoessl, and M. Schulzer. 2008. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann. Neurol. 63:388-394.
62. McGeer, P. L., C. Schwab, A. Parent, and D. Doudet. 2003. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine administration. Ann. Neurol. 54:599-604.
63. Mikolaenko, I., O. Pletnikova, C. H. Kawas, R. O'Brien, S. M. Resnick, B. Crain, et al. 2005. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J. Neuropathol. Exp. Neurol. 64:156-162.
64. Miller, G. W., J. D. Erickson, J. T. Perez, S. N. Penland, D. C. Mash, D. B. Rye, et al. 1999. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156:138-148.
65. Minghetti, L., M. A. Ajmone-Cat, M. A. De Berardinis, and R. De Simone. 2005. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Brain Res. Rev. 48:251-256.
66. Mogi, M., M. Harada, T. Kondo, P. Riederer, H. Inagaki, M. Minami, et al. 1994. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:147-150.
67. Müller, T., S. Sällström Baum, P. Häussermann, D. Woitalla, H. Rommelspacher, H. Przuntek, et al. 1998. Plasma levels of R- and S-salsolinol are not increased in "de-novo" Parkinsonian patients. J. Neural Transm. 105:239-246.
68. Nagatsu, T., M. Mogi, H. Ichinose, and A. Togari. 2000. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. 143-151.
69. Nguyen-Legros, J., J. Bizot, M. Bolesse, and J. P. Pulicani. 1980. "Diaminobenzidine black" as a new histochemical demonstration of exogenous iron (author's transl). Histochemistry 66:239-244.
70. Nurmi, E., H. M. Ruottinen, V. Kaasinen, J. Bergman, M. Haaparanta, O. Solin, et al. 2000. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann. Neurol. 47:804-808.
71. Okamura, N., V. L. Villemagne, J. Drago, S. Pejoska, R. K. Dhamija, R. S. Mulligan, et al. 2010. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J. Nucl. Med. 51:223-228.
72. Parker, W. D., Jr., S. J. Boyson, and J. K. Parks. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26:719-723.
73. Perier, C., J. Bové, D. C. Wu, B. Dehay, D. K. Choi, V. Jackson-Lewis, et al. 2007. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc. Natl. Acad. Sci. U S A 104:8161-8166.
74. Phinney, A. L., G. Andringa, J. G. Bol, E. Wolters, F. L. van Muiswinkel, A. M. van Dam, et al. 2006. Enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity with aging. Parkinsonism Relat. Disord. 12:228-238.
75. Schapira, A. H., J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269.
76. Schapira, A. H., J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, and C. D. Marsden. 1990. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54:823-827.
77. Schindelin, J., I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, et al. (2012). Fiji: an open-source platform for biological-image analysis. Nat. Meth 9:676-682.
78. Sherer, T. B., R. Betarbet, A. K. Stout, S. Lund, M. Baptista, A. V. Panov, et al. 2002. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22:7006-7015.
79. Sherer, T. B., J. H. Kim, R. Betarbet, and J. T. Greenamyre. 2003a. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179:9-16.
80. Sherer, T. B., R. Betarbet, J. H. Kim, and J. T. Greenamyre. 2003b. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 341:87-90.
81. Sherer, T. B., R. Betarbet, C. M. Testa, B. B. Seo, J. R. Richardson, J. H. Kim, et al. 2003c. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23:10756-10764.
82. Shoffner, J. M., R. L. Watts, J. L. Juncos, A. Torroni, and D. C. Wallace. 1991. Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. 30:332-339.
83. Sofic, E., W. Paulus, K. Jellinger, P. Riederer, and M. B. Youdim. 1991. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:978-982.
84. Song, N., H. Jiang, J. Wang, and J. X. Xie. 2007. Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J. Neurosci. Res. 85:3118-3126.
85. Spillantini, M. G., M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
86. Swant, J., J. S. Goodwin, A. North, A. A. Ali, J. Gamble-George, S. Chirwa, et al. 2011. Alpha-synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J. Biol. Chem. 286:43933-43943.
87. Swerdlow, R. H., J. K. Parks, S. W. Miller, J. B. Tuttle, P. A. Trimmer, J. P. Sheehan, et al. 1996. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40:663-671.
88. Rasband, W. S. 1997-2012. ImageJ. U. S. National Institutes of Health. Bethesda, MA. Available via http://imagej.nih.gov/ij/.
89. Tansey, M. G., M. K. McCoy, and T. C. Frank-Cannon. 2007. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 208:1-25.
90. Taylor, T. N., W. M. Caudle, and G. W. Miller. 2011. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis. 2011:124165.
91. Testa, C. M., T. B. Sherer, and J. T. Greenamyre. 2005. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 134:109-118.
92. Thal, D. R., K. Del Tredici, and H. Braak. 2004. Neurodegeneration in normal brain aging and disease. Sci. Aging Knowledge Environ. 2004:pe26.
93. Tofaris, G. K., P. Garcia Reitbock, T. Humby, S. L. Lambourne, M. O'Connell, B. Ghetti, et al. 2006. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26:3942-3950.
94. Trojanowski, J. Q., M. Goedert, T. Iwatsubo, and V. M. Lee. 1998. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death Differ. 5:832-837.
95. Van Den Eeden, S. K., C. M. Tanner, A. L. Bernstein, R. D. Fross, A. Leimpeter, D. A. Bloch, et al. 2003. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157:1015-1022.
96. Vila, M., V. Jackson-Lewis, C. Guégan, D. C. Wu, P. Teismann, D. K. Choi, et al. 2001. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14:483-489.
97. Wersinger, C., and A. Sidhu. 2003. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 340:189-192.
98. Whitton, P. S. 2007. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150:963-976.
99. Winogrodzka, A., P. Bergmans, J. Booij, E. A. van Royen, A. G. Janssen, and E. C. Wolters. 2001. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J. Neural Transm. 108:1011-1019.
100. Wu, D. C., P. Teismann, K. Tieu, M. Vila, V. Jackson-Lewis, H. Ischiropoulos, et al. 2003. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U S A 100:6145-6150.
101. Yang, L., N. Y. Calingasan, J. Chen, J. J. Ley, D. A. Becker, and M. F. Beal. 2005. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. 191:86-93.
102. Zhang, J., G. Perry, M. A. Smith, D. Robertson, S. J. Olson, D. G. Graham, et al. 1999. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154:1423-1429.
103. Zhou, F., J. Y. Wu, X. L. Sun, H. H. Yao, J. H. Ding, and G. Hu. 2007. Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 32:2570-2580.
104. Zhu, C., P. Vourc'h, P. O. Fernagut, S. M. Fleming, S. Lacan, C. D. Dicarlo, et al. 2004. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J. Comp. Neurol. 478:418-426.